North Capital Inc. Acquires Shares of 163 Stryker Corporation (NYSE:SYK)

North Capital Inc. purchased a new position in shares of Stryker Corporation (NYSE:SYK) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 163 shares of the medical technology company’s stock, valued at approximately $61,000.

Several other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Stryker by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company’s stock valued at $11,773,213,000 after acquiring an additional 252,188 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Stryker by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,109,722 shares of the medical technology company’s stock worth $4,000,056,000 after acquiring an additional 54,693 shares during the last quarter. FMR LLC raised its holdings in shares of Stryker by 10.0% in the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company’s stock worth $2,892,946,000 after acquiring an additional 727,850 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Stryker by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 7,073,562 shares of the medical technology company’s stock worth $2,539,033,000 after acquiring an additional 168,436 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Stryker in the 4th quarter worth about $1,710,744,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.90% of the stock is owned by insiders.

Stryker Price Performance

SYK stock opened at $392.00 on Friday. The company has a fifty day simple moving average of $382.39 and a two-hundred day simple moving average of $375.99. The firm has a market capitalization of $149.62 billion, a P/E ratio of 52.97, a price-to-earnings-growth ratio of 2.95 and a beta of 0.91. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69. Stryker Corporation has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The business’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business earned $2.50 EPS. Analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker’s payout ratio is 45.41%.

Wall Street Analyst Weigh In

SYK has been the subject of several analyst reports. Citigroup reiterated a “buy” rating and issued a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research note on Monday, May 5th. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a “buy” rating in a research note on Monday, April 14th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Finally, Roth Mkm increased their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.